Cancer stem cells at the root of cancer

accreditation
iStock

Although the very concept of cancer stem cells has been controversial, new research provides proof that these distinct types of cells exist in humans.

Using genetic tracking, researchers found that a gene mutation tied to cancer's development can be traced back to cancer stem cells. These cells are at the root of cancer and responsible for supporting the growth and progression of the disease, the scientists report.

Cancer stem cells are able to replenish themselves and produce other types of cancer cells, just as healthy cells produce other normal cells, the study's British and European authors explained.

Targeting cancer stem cells

"It's like having dandelions in your lawn. You can pull out as many as you want, but if you don't get the roots they'll come back," study first author Dr Petter Woll, of the MRC Weatherall Institute for Molecular Medicine at the University of Oxford, said in a university news release.

The researchers, led by a team of scientists at Oxford and the Karolinska Institute in Sweden, said their findings could have significant implications for cancer treatment. They explained that by targeting cancer stem cells, doctors could not only get rid of a patient's cancer but also prevent any remaining cancer cells from sustaining the disease.

The study, published in Cancer Cell, involved 15 patients diagnosed with myelodysplastic syndromes (MDS), a type of cancer that often develops into acute myeloid leukaemia, a form of blood cancer.

Read: Stem cell technology may help immune cells

The researchers examined the cancer cells in the patients' bone marrow. Four of the patients were also monitored over time. One patient was followed for two years. Two patients were followed for 30 months and another patient was monitored for 10 years.

Unreliable lab tests

According to the researchers, in prior studies citing the existence of cancer stem cells, the lab tests that were used to identify these cells were considered by many to be unreliable.

However, "In our studies we avoided the problem of unreliable lab tests by tracking the origin and development of cancer-driving mutations in MDS patients," explained study leader Sten Eirik Jacobsen, of Oxford's MRC Molecular Haematology Unit and the Weatherall Institute for Molecular Medicine.

According to the research, a distinct group of MDS cells had all the characteristics of cancer stem cells, and only these particular cancer cells appeared able to cause tumour spread.

The researchers added that this subset of MDS stem cells was rare, but they could replenish other MDS cancer cells. They were also the root of all genetic mutations that caused the disease to progress.

More efficient treatments needed

"This is conclusive evidence for the existence of cancer stem cells in myelodysplastic syndromes," Woll concluded. "We have identified a subset of cancer cells, shown that these rare cells are invariably the cells in which the cancer originates, and also are the only cancer-propagating cells in the patients. It is a vitally important step because it suggests that if you want to cure patients, you would need to target and remove these cells at the root of the cancer – but that would be sufficient, that would do it."

Although the findings do not offer up any new cancer treatment, the study authors believe they may help scientists develop more efficient treatments that specifically target cancer stem cells.

Read: Stem cell study targets tumours

They stressed, however, that this particular study identified only MDS stem cells – other forms of cancer likely have a unique set of stem cells that work differently, the team said.

"We need to understand more about what makes these cancer stem cells unique, what makes them different to all the other cancer cells," Woll said. "If we can find biological pathways that are specifically dysregulated in cancer stem cells, we might be able to target them with new drugs."

Read more:
Stem-cell therapy wipes out HIV in two patients
Scientists find quicker way to study cancer drivers

World's first chemical guided missile could cure cancer

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Eskom has considered continuous load shedding at Stage 2, instead of introducing it when the power system faces a crunch. What are your thoughts?
Please select an option Oops! Something went wrong, please try again later.
Results
I'm all for it - we're going to have power cuts regardless, so we might as well have some stability to better plan our lives
45% - 4711 votes
No thanks! I prefer having periods of no load shedding and we cannot normalise this crisis
55% - 5782 votes
Vote
Rand - Dollar
18.07
-0.6%
Rand - Pound
19.32
+0.4%
Rand - Euro
17.39
-0.2%
Rand - Aus dollar
11.69
+0.1%
Rand - Yen
0.13
-0.1%
Gold
1,625.99
-1.1%
Silver
18.44
-2.3%
Palladium
2,049.50
-1.1%
Platinum
855.00
-0.4%
Brent Crude
86.15
-5.0%
Top 40
57,290
+0.3%
All Share
63,626
+0.3%
Resource 10
56,215
-0.2%
Industrial 25
79,529
+1.4%
Financial 15
13,982
-1.2%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE